Recent Updates
Recently added Catalysts

Stage IV Merkel Cell Carcinoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$134Muniverse median $1.20B
Allocated capital$134M$134M competing
Phase 3 or filed01 mid, 0 early
Pure plays1this indication only
Capital rank270/299crowding rank 271

Stage IV Merkel Cell Carcinoma is uncontested. TuHURA Biosciences (HURA) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with IFx-Hu2.0 in phase 2.

There is no public comparable to price it against, and HURA runs clinical programmes in this indication and nothing else, so its $134M market cap is a direct read on what the market thinks this programme is worth.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$134M of allocated capital sits in Stage IV Merkel Cell Carcinoma, ranking it 270th of 299 indications by the money committed to it.

Companies developing drugs for Stage IV Merkel Cell Carcinoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
HURATuHURA BiosciencesIFx-Hu2.0Phase 22$134MYes1 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Stage IV Merkel Cell Carcinoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Stage IV Merkel Cell Carcinoma has one competitor and a median of $134M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

T-Cell Lymphoblastic Leukemia/Lymphoma2 companies · $149M · median $374MOrphan cornerWell-differentiated Pancreatic Neuroendocrine Tumor1 company · $119M · median $356MUncontestedRecurrent Cutaneous T-Cell Lymphoma1 company · $119M · median $356MUncontestedRelapsed/Refractory Non-Hodgkin's Lymphoma1 company · $117M · median $351MUncontestedRelapsed and Refractory Multiple Myeloma1 company · $156M · median $156MUncontestedMetastatic Lung Cancer1 company · $162M · median $486MUncontestedHigh-grade Serous Ovarian Cancer1 company · $98M · median $295MUncontestedAdvanced Hepatocellular Carcinoma1 company · $175M · median $175MUncontested

Stage IV Merkel Cell Carcinoma pipeline questions

Which biotech companies are developing drugs for Stage IV Merkel Cell Carcinoma?

TuHURA Biosciences (HURA, IFx-Hu2.0, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Stage IV Merkel Cell Carcinoma.

How advanced is the Stage IV Merkel Cell Carcinoma pipeline?

Of the 1 clinical-stage programme in Stage IV Merkel Cell Carcinoma, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Stage IV Merkel Cell Carcinoma?

No. HURA is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Stage IV Merkel Cell Carcinoma, which is why the indication is classified as uncontested.

When is the next Stage IV Merkel Cell Carcinoma catalyst?

The next dated catalyst in Stage IV Merkel Cell Carcinoma is HURA on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map